+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID07416695

Phase I Study of HLX3901 Given by IV Infusion in Adults With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma

Led by Shanghai Henlius Biotech · Updated on 2026-07-08

138

Participants Needed

2

Research Sites

56 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying HLX3901 in an open-label, first-in-human phase I clinical trial involving patients with advanced small cell lung cancer SCLC or neuroendocrine carcinoma NEC. The study aims to evaluate the safety, tolerability, and how the drug behaves in the body, focusing on patients who have experienced intolerance, recurrence, or disease progression after prior treatments. The study has two parts Phase Ia uses dose escalation and backfill cohorts where patients receive HLX3901 via intravenous infusion at increasing doses, observing dose-limiting toxicities over 4 weeks. Phase Ib expands the dose to confirm safety and efficacy of HLX3901 monotherapy in selected groups based on Phase Ia data. Participants receive the recommended Phase 2 dose RP2D identified during dose escalation. Participants will undergo screening, treatment cycles of 4 weeks, and monitoring of side effects and tumor response using objective response rates and survival measures over approximately 24 months. Safety reviews guide dosing decisions, and tumor tissue will be collected to test for DLL3 expression. The study involves regular assessments including laboratory tests and imaging to monitor health and treatment effects throughout participation, which can last up to about two years.

CONDITIONS

Brief Title

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here